Teva Pharmaceutical Industries (TEVA) said Tuesday that it has started preclinical "IND-enabling" studies for BD9, an experimental treatment for atopic dermatitis and asthma developed in partnership with Biolojic Design.
Teva said the investigational therapy, known as BD9, targets IL-13 and TSLP, two proteins associated with TH2-driven inflammation.
Teva has exclusive global development rights to the drug through a licensing agreement with Biolojic and Biolojic may receive milestone payments tied to BD9's progress through development and commercialization, Teva said.
Shares of Teva were up 2.7% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.